Isidori Andrea M, Kaltsas Gregory A, Pozza Carlotta, Frajese Vanni, Newell-Price John, Reznek Rodney H, Jenkins Paul J, Monson John P, Grossman Ashley B, Besser G Michael
Department of Endocrinology, St. Bartholomew's Hospital, London EC1A 7BE, United Kingdom.
J Clin Endocrinol Metab. 2006 Feb;91(2):371-7. doi: 10.1210/jc.2005-1542. Epub 2005 Nov 22.
There are few large series of patients with ectopic, nonpituitary, corticotropin (ACTH) secretion (EAS).
The objective of this study was to analyze the clinical, biochemical, and radiological features, management, and treatment outcome of patients with EAS.
This was a retrospective case-record study.
The setting for this study was a tertiary referral hospital center.
Forty patients with EAS were studied.
Clinical, biochemical, and radiological features and response to therapy and survival were measured.
The median follow-up was 5 yr (range, 2-30 yr). None of the dynamic tests achieved 100% accuracy, but bilateral inferior petrosal sinus sampling showed an absent central gradient in all but one case (one of 12). Imaging correctly identified the lesion at first investigation in 65% of cases. Bronchial carcinoid tumors were the most common cause of EAS (n = 12; 30%), followed by other neuroendocrine tumors (n = 13, 32.5%). In 12.5% of patients, the source of EAS was never found. Octreotide scintigraphy and whole-body venous sampling were of limited value. Surgical attempt at curative resection was successful in 83% (10 of 12) of patients with bronchial carcinoid tumors; others responded generally well to adrenolytic therapy or bilateral adrenalectomy. Tumor histology and the presence of distant metastases were the main predictors of overall survival (P < 0.05).
A variety of tests and imaging studies are necessary for the correct diagnosis of the EAS, but even then, up to 20% of cases present a covert or occult EAS syndrome. These cases require a prolonged follow-up, review, and repetition of diagnostic tests and scans.
异位、非垂体促肾上腺皮质激素(ACTH)分泌(EAS)的患者大样本系列研究较少。
本研究旨在分析EAS患者的临床、生化和放射学特征、管理及治疗结果。
这是一项回顾性病例记录研究。
本研究的地点是一家三级转诊医院中心。
对40例EAS患者进行了研究。
测量临床、生化和放射学特征以及对治疗的反应和生存率。
中位随访时间为5年(范围为2至30年)。没有一项动态试验能达到100%的准确性,但双侧岩下窦采血显示,除1例(12例中的1例)外,其余所有病例的中心梯度均不存在。在65%的病例中,影像学检查在首次检查时正确识别了病变。支气管类癌瘤是EAS最常见的病因(n = 12;30%),其次是其他神经内分泌肿瘤(n = 13,32.5%)。在12.5%的患者中,从未找到EAS的来源。奥曲肽闪烁扫描和全身静脉采血价值有限。对于支气管类癌瘤患者,83%(12例中的10例)进行根治性切除的手术尝试成功;其他患者对肾上腺溶解疗法或双侧肾上腺切除术反应总体良好。肿瘤组织学和远处转移的存在是总生存的主要预测因素(P < 0.05)。
正确诊断EAS需要多种检查和影像学研究,但即便如此,仍有高达20%的病例表现为隐匿性或隐性EAS综合征。这些病例需要长期随访、复查以及重复诊断检查和扫描。